As Ki67 has been clinically utilized to define highly proliferative breast cancers (33), we previously reported that Ki67 decrease during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with LABC (34). The gene discussed is MKI67; the disease is breast cancer.